Skip to main content
SpringerLink
Log in

New p53-based anti-cancer therapeutic strategies

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Thep53 gene is frequently mutated in human tumours and therefore an important target for therapeutic intervention. Several p53-based strategies for treatment of cancer are currently under development.p53 gene therapy has resulted in tumour regression in patients with lung cancer. A mutant adenovirus can obliterate tumour cells carrying mutant p53 or lacking p53, but is unable to replicate in normal cells. Furthermore, current studies suggest that reactivation of mutant p53 proteins in tumours using small p53-activating molecules may initiate p53-dependent apoptosis and thus eliminate the tumour.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ko LJ, Prives C. p53: puzzle and paradigm.Genes Dev 1996;10: 1054–1072.

    Article  CAS  PubMed  Google Scholar 

  2. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53.Cell 1992;71: 875–886.

    Article  CAS  PubMed  Google Scholar 

  3. Selivanova Get al. The single stranded DNA end binding site of p53 coincides with the C-terminal regulatory region.Nucleic Acids Res 1996;24: 3560–3567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. El-Deiry WSet al. WAF1, a potential mediator of p53 tumor suppression.Cell 1993;75: 817–825.

    Article  CAS  PubMed  Google Scholar 

  5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.Cell 1993;75: 805–816.

    Article  CAS  PubMed  Google Scholar 

  6. Sherr CJ. Cancer cell cycles.Science 1996;274: 1672–1677.

    Article  CAS  PubMed  Google Scholar 

  7. Smith MLet al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen.Science 1994;266: 1376–1380.

    Article  CAS  PubMed  Google Scholar 

  8. Hermeking Het al. 14-3-3σ is a p53-regulated inhibitor of G2/M progression.Mol Cell 1997;1: 3–11.

    Article  CAS  PubMed  Google Scholar 

  9. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene.Cell 1995;80: 293–299.

    Article  CAS  PubMed  Google Scholar 

  10. Knudson CMet al. Bax-deficient mice with lymphoid hyperplasia and male germ cell death.Science 1995;270: 96–99.

    Article  CAS  PubMed  Google Scholar 

  11. Yin C, Knudson CM, Korsmeyer SJ, Van Dyke T. Bax suppresses tumorigenesis and stimulates apoptosisin vivo.Nature 1996;385: 637–640.

    Article  Google Scholar 

  12. Buckbinder Let al. Induction of the growth inhibitor IGF-binding protein 3 by p53.Nature 1995;377: 646–649.

    Article  CAS  PubMed  Google Scholar 

  13. Owen-Schaub LBet al. Wild type human p53 and a temperature-sensitive mutant induce fas/APO-1 expression.Mol Cell Biol 1995;15: 3032–3040.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis.Nature 1997;389: 300–305.

    Article  CAS  PubMed  Google Scholar 

  15. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determines the extent of the apoptotic response of tumor cells.Genes Dev 1996;10: 2438–2451.

    Article  CAS  PubMed  Google Scholar 

  16. Walker KK, Levine AJ. Identification of a novel p53 functional domain that is necessary for efficient growth suppression.Proc Natl Acad Sci USA 1996;93: 15335–15340.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sakamuro D, Sabbatini P, White E, Prendergast GC. The polyproline region of p53 is required to activate apoptosis but not growth arrest.Oncogene 1997;15: 887–898.

    Article  CAS  PubMed  Google Scholar 

  18. Wu X, Bayle H, Olson D, Levine AJ. The p53-mdm2 autoregulatory loop.Genes Dev 1993;7: 1126–1132.

    Article  CAS  PubMed  Google Scholar 

  19. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53.Nature 1997;387: 296–299.

    Article  CAS  PubMed  Google Scholar 

  20. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability of Mdm2.Nature 1997;387: 299–303.

    Article  CAS  PubMed  Google Scholar 

  21. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.Science 1994;265: 364–355.

    Article  Google Scholar 

  22. Vousden KH. Interactions of human papilloma virus transforming proteins with the products of tumor suppressor genes.FASEB J 1994;7: 872–879.

    Article  Google Scholar 

  23. Selivanova G, Wiman KG. p53: a cell cycle regulator activated by DNA damage.Adv Cancer Res 1995;66: 143–180.

    Article  CAS  PubMed  Google Scholar 

  24. Eckner Ret al. Molecular cloning and functional analysis of the adenovirus E1A-associated 300kD protein (p300) reveals a protein with properties of a transcriptional adaptor.Genes Dev 1994;8: 869–884.

    Article  CAS  PubMed  Google Scholar 

  25. Gu W, Shi X-L, Roeder RG. Synergistic activation of transcription by CBP and p53.Nature 1997;387: 819–823.

    Article  CAS  PubMed  Google Scholar 

  26. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators.Nature 1997;387: 823–827.

    Article  CAS  PubMed  Google Scholar 

  27. Lowe SW, Ruley HE. Stabilization of the p53 tumor suppressor is induced by adenovirus E1A and accompanies apoptosis.Genes Dev 1993;7: 535–545.

    Article  CAS  PubMed  Google Scholar 

  28. Debbas M, White E. Wild type p53 mediates apoptosis by E1A which is inhibited by E1B.Genes Dev 1993;7: 546–554.

    Article  CAS  PubMed  Google Scholar 

  29. Roth JAet al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.Nat Med 1996;2: 985–991.

    Article  CAS  PubMed  Google Scholar 

  30. Haupt Y, Rowan S, Oren M. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB.Oncogene 1995;10: 1563–1571.

    CAS  PubMed  Google Scholar 

  31. Sandig Vet al. Adenovirally transferred p16INK4a and p53 genes cooperate to induce apoptotic tumor cell death.Nat Med 1997;3: 313–319.

    Article  CAS  PubMed  Google Scholar 

  32. Yew PR, Berk AJ. Inhibition of p53 transactivation required for transformation by adenovirus early E1B protein.Nature 1992;357: 82–85.

    Article  CAS  PubMed  Google Scholar 

  33. Bischoff JRet al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells.Science 1996;274: 373–376.

    Article  CAS  PubMed  Google Scholar 

  34. Heise Cet al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents.Nat Med 1997;3: 639–645.

    Article  CAS  PubMed  Google Scholar 

  35. Lowe SW. Progress of the smart bomb cancer virus.Nat Med 1997;3: 606–608.

    Article  CAS  PubMed  Google Scholar 

  36. Halazonetis TD, Davis LJ, Kandil AN. Wild type p53 adopts a ‘mutant’-like conformation when bound to DNA.EMBO J 1993;12: 1021–1028.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Halazonetis TD, Kandil AN. Conformational shifts propagate form the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select mutant p53.EMBO J 1993;12: 5057–5064.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Waterman JLF, Shenk JL, Halazonetis TD. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding.EMBO J 1995;14: 512–519.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Hupp TR, Lane DP. Allosteric activation of latent p53 tetramers.Curr Biol 1994;4: 865–875.

    Article  CAS  PubMed  Google Scholar 

  40. Takenaka I, Morin F, Seizinger BR, Kley N. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases.J Biol Chem 1995;270: 5405–5411.

    Article  CAS  PubMed  Google Scholar 

  41. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain.Cell 1997;90: 595–606.

    Article  CAS  PubMed  Google Scholar 

  42. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53.Cell 1995;83: 237–245.

    Article  CAS  PubMed  Google Scholar 

  43. Waterman MJF, Stavridi ES, Waterman JLF, Halazonetis TD. ATM-dependent activation of p53 involves dephosphorylation o and association with 14-3-3 proteins.Nat Genet 1998;19: 175–178.

    Article  CAS  PubMed  Google Scholar 

  44. Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant forms of p53.Nucleic Acids Res 1993;21: 3167–3174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Abarzua Pet al. Restoration of the transcription activation function to mutant p53 in human cancer cells.Oncogene 1996;13: 2477–2482.

    CAS  PubMed  Google Scholar 

  46. Abarzua P, LoSardo JE, Gubler ML, Neri A. Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription transactivation function to mutant p53.Cancer Res 1995;55: 3490–3494.

    CAS  PubMed  Google Scholar 

  47. Selivanova Get al. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain.Nat Med 1997;3: 632–638.

    Article  CAS  PubMed  Google Scholar 

  48. Wieczorek AM, Waterman JLF, Waterman MJF, Halazonetis TD. Structure-based rescue of common tumorderived p53 mutants.Nat Med 1996;2: 1143–1146.

    Article  CAS  PubMed  Google Scholar 

  49. Barinaga M. From bench top to bedside.Science 1997;278: 1036–1039.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Microbiology and Tumor Biology Center, Karolinska Institute, Stockholm, Sweden

    Klas G Wiman

Authors
  1. Klas G Wiman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Klas G Wiman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wiman, K.G. New p53-based anti-cancer therapeutic strategies. Med Oncol 15, 222–228 (1998). https://doi.org/10.1007/BF02787204

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02787204

Keywords

Search

Navigation